EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Jordi Remon*, Lizza E. L. Hendriks, Andres F. Cardona, Benjamin Besse

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Article number102105
Number of pages10
JournalCancer Treatment Reviews
Volume90
DOIs
Publication statusPublished - Nov 2020

Keywords

  • EGFR exon 20 insertions
  • Poziotinib
  • TAK-788
  • Amivantamab
  • Osimertinib
  • PLUS CETUXIMAB
  • MOLECULAR CHARACTERISTICS
  • ACQUIRED-RESISTANCE
  • 1ST-LINE TREATMENT
  • OPEN-LABEL
  • MUTATION
  • AFATINIB
  • ADENOCARCINOMA
  • OSIMERTINIB
  • POZIOTINIB

Cite this